Streamlining Progress in Neuroscience Visit our poster TODAY at the American Epilepsy Society 2024 Congress Poster #: 2.349 Date: Sunday, December 8, 2024 Presentation Time: 12:00–2:00 PM PST Discover the three-fold innovation breaking barriers in epilepsy treatment: -First-in-class novel intracellular therapeutic approach -Allosteric mechanism of action enabling selective target engagement -Trifecta of benefit: seizure control, cognitive enhancement, and improved well-being (preclinical model) We look forward to sharing how our groundbreaking work is advancing epilepsy care!
Stream Neuroscience
Biotechnology Research
Calgary, AB 32 followers
The future of neuroscience therapies is inside the cell
About us
Stream Neuroscience is a private international biotechnology company specializing in development of new medicines for tough-to-treat neurological disorders. Most conventional neurological therapies target proteins on the cell surface to influence a few biological pathways. Stream Neuroscience's powerful new therapies delve deep inside the cell to activate crucial signalling molecules, allowing for regulation of several biological pathways responsible for neurological disease. Our data show pre-clinical efficacy for treatment of Dravet Syndrome, Focal Onset Epilepsy, and improvement of cognition. Learn more about our innovative treatments, science, and team.
- Website
-
https://streamneurosci.com/
External link for Stream Neuroscience
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Calgary, AB
- Type
- Privately Held
- Founded
- 2024
Locations
-
Primary
Get directions
Calgary, AB T3Z 2T2, CA
-
Get directions
DeKalb, Illinois 60115, US
Employees at Stream Neuroscience
Updates
-
💡 The Future of Neuroscience Therapies is Inside the Cell - Learn about Stream Neuroscience's lead program: Selective inhibition of PDE4 for treatment of epilepsies. 🧠 Conventional epilepsy treatments target membrane-bound proteins. Stream Neuroscience is revolutionizing epilepsy therapeutics by turning the focus inwards - Inside the cell, that is! ⚡ Phosphodiesterase 4 (PDE4) is an enzyme that clears cyclic adenosine monophosphate (cAMP), a crucial intracellular signalling molecule, from cells. cAMP controls many pathways associated with brain health including neuronal excitatory/inhibitory signalling, neuronal survival, synaptic plasticity, and neuroinflammation. 💊 Stream Neuroscience’s novel treatments are allosteric Phosphodiesterase 4 inhibitors (PDE4is). PDE4is reduce the activity of PDE4 leading to increased cAMP levels, termination of epileptic seizures and enhanced cognition.
-
-
💡 How is Stream Neuroscience's approach to PDE4 inhibition different? 💊 PDE4 inhibitors (PDE4i) have gained FDA approval for treatment of COPD, atopic dermatitis, psoriasis and psoriatic arthritis. PDE4i have completed clinical trials in neurological conditions as well, although side effects limited further development. 💪 To circumvent tolerability issues of older PDE4is, the newest generation of PDE4is are rationally designed for 1) isoform-specificity and 2) allosteric binding to regulatory sites on the PDE4 protein. These unique 'isozyme-specific allosteric binding' properties allow achievement of therapeutic drug levels for treatment of neurological disorders with an improved side effect profile.
-